Myxedema coma

Area of Science:

• Endocrinology
• Critical Care Medicine

Background:

• Myxedema coma represents the most severe manifestation of profound hypothyroidism.
• It carries a high mortality rate despite available therapies.
• Precipitating factors include drugs, infections like pneumonia, and other systemic illnesses.

Purpose of the Study:

• To review the presentation, precipitating factors, and management of myxedema coma.
• To highlight the critical need for prompt intensive care unit (ICU) admission.
• To discuss the controversies and essential components of thyroid hormone replacement therapy.

Main Methods:

• Review of clinical presentation and associated signs: hypothermia, hyponatremia, hypercarbia, and hypoxemia.
• Discussion of precipitating factors and patient demographics (older women, winter months).
• Analysis of treatment strategies including thyroid hormone administration and supportive care.

Main Results:

• Myxedema coma typically affects older women, particularly during winter.
• Key clinical signs include hypothermia, electrolyte imbalances, and respiratory compromise.
• While thyroid hormone is essential, the optimal formulation (thyroxine, triiodothyronine, or combination) is not definitively established.

Conclusions:

• Myxedema coma requires immediate ICU management.
• Prompt initiation of thyroid hormone replacement and comprehensive supportive care are vital for survival.
• Further research is needed to clarify the optimal thyroid hormone regimen.